Avanir Pharmaceuticals Upgraded to “Hold” by Jefferson Research (AVNR)
Avanir Pharmaceuticals (NASDAQ:AVNR) was upgraded by investment analysts at Jefferson Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday, Stock Ratings News reports.
Shares of Avanir Pharmaceuticals (NASDAQ:AVNR) traded up 2.74% on Friday, hitting $4.12. The stock had a trading volume of 1,110,874 shares. Avanir Pharmaceuticals has a 52-week low of $2.60 and a 52-week high of $6.00. The stock’s 50-day moving average is $3.53 and its 200-day moving average is $4.23. The company’s market cap is $626.7 million.
Avanir Pharmaceuticals (NASDAQ:AVNR) last announced its earnings results on Wednesday, February 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by $0.50. The company had revenue of $26.70 million for the quarter, compared to the consensus estimate of $24.84 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. On average, analysts predict that Avanir Pharmaceuticals will post $-0.29 earnings per share for the current fiscal year.
AVNR has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Avanir Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Thursday, January 9th. They now have a $3.20 price target on the stock. Finally, analysts at Summer Street cut their price target on shares of Avanir Pharmaceuticals to $10.00 in a research note on Wednesday, December 11th. They now have a “buy” rating on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Avanir Pharmaceuticals currently has an average rating of “Buy” and an average price target of $7.95.
AVANIR Pharmaceuticals, Inc (NASDAQ:AVNR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.